Adaptive Dengue Antiviral Platform Trial

Inclusion Criteria:

* Female or male patients with a clinical diagnosis of dengue virus infection and less than 48 hours of fever
* Positive NS1 rapid diagnostic test
* \>= 10 years or ≥ 18 years of age (depending on license of therapeutic being evaluated)
* Patient is able to give written informed consent or assent for full participation in the study.
* Agreement to stay in hospital for duration of the intervention (most will be 5 days) and follow-up visits at day 30 and 60 post enrolment.

Exclusion Criteria:

* Meets criteria for severe dengue at baseline (severe plasma leakage leading to dengue shock syndrome, fluid accumulation with respiratory distress, severe bleeding, severe organ involvement - AST/ALT\>1000 U/L, impaired consciousness, multiple organ dysfunction)
* Pregnancy (either clinically confirmed or by urine dipstick for human chorionic gonadotrophin hormone)
* Breastfeeding women
* Localising features suggesting an alternative/additional diagnosis, e.g. pneumonia, sepsis
* Renal failure (baseline eGFR \< 30ml/min)
* History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, neuropsychiatric, autoimmune, dermatologic or immunosuppressive disorders
* History of allergic disease, allergic reactions or known hypersensitivity to any component of the study product (Mild non-medication allergies allowed)
* Any condition that, in the opinion of the investigator, would complicate or compromise the study or well-being of the participant
* Participation or planned participation in a study involving the administration of an investigational compound within the past one month.